DrugPatentWatch Database Preview
ELLA Drug Profile
see a sample report or, see our see our flat-rate plans
When do Ella patents expire, and what generic alternatives are available?
This drug has sixty-three patent family members in twenty-seven countries.
The generic ingredient in ELLA is ulipristal acetate. There are five drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the ulipristal acetate profile page.
Summary for ELLA
| International Patents: | 63 |
| US Patents: | 5 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 2 |
| Bulk Api Vendors: | 52 |
| Patent Applications: | 46 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for ELLA |
| DailyMed Link: | ELLA at DailyMed |
Pharmacology for ELLA
| Drug Class | Progesterone Agonist/Antagonist |
| Mechanism of Action | Selective Progesterone Receptor Modulators |
Synonyms for ELLA
| (10S,11S,14R,15S,17R)-14-acetyl-17-[4-(dimethylamino)phenyl]-15-methyl-5-oxotetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-1,6-dien-14-yl acetate |
| (10S,11S,14R,15S,17R)-14-acetyl-17-[4-(dimethylamino)phenyl]-15-methyl-5-oxotetracyclo[8.7.0.0?,?.0??,??]heptadeca-1,6-dien-14-yl acetate |
| (10S,11S,14R,15S,17R)-14-ACETYL-17-[4-(DIMETHYLAMINO)PHENYL]-15-METHYL-5-OXOTETRACYCLO[8.7.0.0(2),?.0(1)(1),(1)?]HEPTADECA-1,6-DIEN-14-YL ACETATE |
| (11beta,17alpha)-17-acetyl-11-[4-(dimethylamino)phenyl]-3-oxoestra-4,9-dien-17-yl acetate |
| (11beta)-17-(Acetyloxy)-11-(4-(dimethylamino)phenyl)-19-norpregna-4,9-diene-3,20-dione |
| (11beta)-17-(Acetyloxy)-11-[4-(dimethylamino)phenyl]-19-norpregna-4,9-diene-3,20-dione |
| (8S,11R,13S,14S,17R)-17-acetyl-11-(4-(dimethylamino)phenyl)-13-methyl-3-oxo-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl acetate |
| [(8S,11R,13S,14S,17R)-17-acetyl-11-(4-dimethylaminophenyl)-13-methyl-3-oxo-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-17-yl] acetate |
| 126784-99-4 |
| 17-Acetoxy-11-(4-N,N-dimethylaminophenyl)pregna-4,9-diene-3,20-dione |
| 17beta-acetyl-11beta-[4-(dimethylamino)phenyl]-3-oxoestra-4,9-dien-17alpha-yl acetate |
| 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-(4-(dimethylamino)phenyl)-, (11beta)- |
| 19-Norpregna-4,9-diene-3,20-dione,17-(acetyloxy)-11-[4-(dimethylamino)phenyl]-, (11b)- |
| 3B1-000818 |
| 4oar |
| 5-(Hydroxymethyl)-alpha,alpha,alpha,alpha-tetramethyl-1,3-benzenediacetonitrile |
| 784A994 |
| AB01566874_01 |
| AC1L2Y8A |
| AKOS026750526 |
| AMX10180 |
| BDBM50375424 |
| C30H37NO4 |
| CBD 2914; VA 2914; (11b)-17-(Acetyloxy)-11-[4-(dimethylamino)phenyl]-19-norpregna-4,9-diene-3,20-dione |
| CDB 2914 |
| CDB-2914 |
| CHEBI:71025 |
| CHEMBL260538 |
| CS-1157 |
| D09687 |
| DTXSID30155294 |
| EllaOne |
| EllaOne|||Esmya |
| EN300-220766 |
| Esmya |
| FT-0675731 |
| GTPL7460 |
| Hrp-2000 |
| HY-16508 |
| J-005436 |
| KB-81383 |
| KS-00000Z24 |
| MolPort-006-170-077 |
| OOLLAFOLCSJHRE-ZHAKMVSLSA-N |
| PL009540 |
| RTI 3021-012 |
| SC-44720 |
| SCHEMBL544957 |
| U0102 |
| Ulipristal (acetate) |
| Ulipristal acet |
| Ulipristal acetate |
| Ulipristal acetate (JAN/USAN) |
| Ulipristal acetate [USAN] |
| Ulipristal acetate, >=98% (HPLC) |
| Ulipristal acetate(CDB2914) |
| Ulipristal-Acetate |
| UNII-YF7V70N02B |
| VA2914 |
| W-5201 |
| X4788 |
| YF7V70N02B |
| Z2216208644 |
| ZINC3920657 |
US Patents and Regulatory Information for ELLA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lab Hra Pharma | ELLA | ulipristal acetate | TABLET;ORAL | 022474-001 | Aug 13, 2010 | AB | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | |||
| Lab Hra Pharma | ELLA | ulipristal acetate | TABLET;ORAL | 022474-001 | Aug 13, 2010 | AB | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | ||
| Lab Hra Pharma | ELLA | ulipristal acetate | TABLET;ORAL | 022474-001 | Aug 13, 2010 | AB | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | |||
| Lab Hra Pharma | ELLA | ulipristal acetate | TABLET;ORAL | 022474-001 | Aug 13, 2010 | AB | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | |||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
see a sample report or, see our see our flat-rate plans
Paragraph IV (Patent) Challenges for ELLA
| Drugname | Dosage | Strength | RLD | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 30 mg | ➤ Subscribe | 2014-08-13 |
Non-Orange Book US Patents for ELLA
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
see a sample report or, see our see our flat-rate plans
